The Steady-State Comparative Bioavailability of Intramuscular Risperidone ISM and Oral Risperidone: An Open-Label, One-Sequence Study

References

• Ascher-SvanumH, FariesDE, ZhuB, ErnstFR, SwartzMS, SwansonJW. Medication adherence and long-term functional outcomes in the treatment of schizophrenia in usual care. J Clin Psychiatry. 2006;67(3):453–460. doi:10.4088/JCP.v67n031716649833
   PubMed Web of Science ®Google Scholar
• CorrellCU, CitromeL, HaddadPM, et al. The use of long-acting injectable antipsychotics in schizophrenia: evaluating the evidence. J Clin Psychiatry. 2016;77(Suppl 3):1–24. doi:10.4088/JCP.15032su127732772
   PubMed Web of Science ®Google Scholar
• CorrellCU, KimE, SliwaJK, et al. Pharmacokinetic characteristics of long-acting injectable antipsychotics for schizophrenia: an overview. CNS Drugs. 2021;35:39–59. doi:10.1007/s40263-020-00779-533507525
   PubMed Web of Science ®Google Scholar
• LlaudóJ, AntaL, AyaniI, et al. Open-label, randomized, parallel study to evaluate the pharmacokinetics, safety, and tolerability of one intramuscular injection of risperidone ISM at different dose strengths in patients with schizophrenia or schizoaffective disorder (PRISMA-1). Int Clin Psychopharmacol. 2016;31:323–331. doi:10.1097/YIC.000000000000013927416102
   PubMed Web of Science ®Google Scholar
• AntaL, LlaudóJ, AyaniI, MartínezJ, LitmanRE, GutierroI. A Phase II study to evaluate the pharmacokinetics, safety, and tolerability of risperidone ISM multiple intramuscular injections once every 4 weeks in patients with schizophrenia. Int Clin Psychopharmacol. 2018;33:9–87.
   Web of Science ®Google Scholar
• AntaL, MataE, Ochoa Díaz de MonasteriogurenL. Newer Formulations of risperidone: remarks about risperidone ISM. CNS Drugs. 2020;34(10):1087–1088. doi:10.1007/s40263-020-00762-032892315
   PubMed Web of Science ®Google Scholar
• GuyW. The Clinician Global Severity and Impression Scales. ECDEU Assessment Manual for Psychopharmacology. Superintendent of Documents, IS Government Printing Office, Publication No. 76-338. Washington, DC: US Department of Health, Education, and Welfare; 1976a:218–222.
   Google Scholar
• PosnerK, OquendoMA, GouldM, StanleyB, DaviesM. Columbia Classification Algorithm of Suicide Assessment (C-CASA): classification of suicidal events in the FDA’s pediatric suicidal risk analysis of antidepressants. Am J Psychiatry. 2007;164:1035–1043. doi:10.1176/ajp.2007.164.7.103517606655
   PubMed Web of Science ®Google Scholar
• GuyW. Abnormal Involuntary Movement Scale (AIMS). ECDEU Assessment Manual for Psychopharmacology. Rockville, MD: US Dept. of Health, Education and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, National Institute of Mental Health, Psychopharmacology Research Branch, Division of Extramural Research Programs; 1976b:534–537.
   Google Scholar
• BarnesTR. A rating scale for drug-induced akathisia. Br J Psychiatry. 1989;154:672–676. doi:10.1192/bjp.154.5.6722574607
   PubMed Web of Science ®Google Scholar
• SimpsonGM, AngusJW. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand. 1970;1970(Suppl 212):11–19. doi:10.1111/j.1600-0447.1970.tb02066.x
   Google Scholar
• MagantiL, PanebiancoDL, MaesAL. Evaluation of methods for estimating time to steady-state with examples from Phase 1 studies. AAPS J. 2008;10:141–147. doi:10.1208/s12248-008-9014-y18446514
   PubMed Web of Science ®Google Scholar
• NewlandsA. Statistics and pharmacokinetics in clinical pharmacology studies (paper ST03). Presented at: SAS Conference Proceedings: pharmaceutical Users Software Exchange; PhUSE Dublin; 9–11 October; 2006; Dublin, Ireland.
   Google Scholar
• SamtaniM, GopalS, Gassmann-MayerC, AlphsL, PalumboJM. Dosing and switching strategies for paliperidone palmitate: based on population pharmacokinetic modelling and clinical trial data. CNS Drugs. 2011;25:829–845.21936586
   PubMed Web of Science ®Google Scholar
• Xeplion® summary of product characteristics. Available from: https://www.ema.europa.eu/en/documents/product-information/xeplion-epar-product-information_en.pdf. Accessed July 20, 2021.
   Google Scholar
• Abilify maintena® summary of product characteristics. Available from: https://www.ema.europa.eu/en/documents/product-information/abilify-maintena-epar-product-information_en.pdf. Accessed July 20, 2021.
   Google Scholar
• KramerM, LitmanR, HoughD, et al. Paliperidone palmitate, a potential long-acting treatment for patients with schizophrenia. Results of a randomized, double-blind, placebo-controlled efficacy and safety study. Int J Neuropsychopharmacol. 2010;13(5):635–647. doi:10.1017/S146114570999098819941696
   PubMed Web of Science ®Google Scholar
• Aristada Full Prescribing Information. Available from: https://www.aristadahcp.com/downloadables/ARISTADA-INITIO-PI.pdf. Accessed July 26, 2021.
   Google Scholar
• TavcarR, DernovsekMZ, ZvanV. Choosing antipsychotic maintenance therapy–a naturalistic study. Pharmacopsychiatry. 2000;33(2):66–71. doi:10.1055/s-2000-796910761822
   PubMed Web of Science ®Google Scholar
• EreshefskyL, SakladSR, JannMW, DavisCM, RichardsA, SeidelDR. Future of depot neuroleptic therapy: pharmacokinetic and pharmacodynamic approaches. J Clin Psychiatry. 1984;45:50–59.6143748
   PubMed Web of Science ®Google Scholar
• Risperdal® (oral risperidone) [prescribing information]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020272s085,020588s072,021444s058lbl.pdf. Accessed July 1, 2021.
   Google Scholar
• SongF. Risperidone in the treatment of schizophrenia: a meta-analysis of randomized controlled trials. J Psychopharmacol. 1997;11(1):65–71. doi:10.1177/0269881197011001169097896
   PubMed Web of Science ®Google Scholar
• MamoD, KapurS, KeshavanM, et al. D 2 receptor occupancy of olanzapine pamoate depot using positron emission tomography: an open-label study in patients with schizophrenia. Neuropsychopharmacology. 2008;33(2):298–304. doi:10.1038/sj.npp.130140917443131
   PubMed Web of Science ®Google Scholar
• MamoD, KapurS, ShammiCM, et al. A PET study of dopamine D2 and serotonin 5-HT2 receptor occupancy in patients with schizophrenia treated with therapeutic doses of ziprasidone. Am J Psychiatry. 2004;161(5):818–825. doi:10.1176/appi.ajp.161.5.81815121646
   PubMed Web of Science ®Google Scholar
• ThyssenA, RuschS, HerbenV, QuirozJ, MannaertE. Risperidone long‐acting injection: pharmacokinetics following administration in deltoid versus gluteal muscle in schizophrenic patients. J Clin Pharmacol. 2010;50(9):1011–1021. doi:10.1177/009127000935515620097933
   PubMed Web of Science ®Google Scholar
• BusheC, ShawM, PevelerRC. A review of the association between antipsychotic use and hyperprolactinaemia. J Psychopharmacol. 2008;22(Suppl):46–55. doi:10.1177/026988110708843518477620
   PubMedGoogle Scholar
• HuhnM, NikolakopoulouA, Schneider-ThomaJ, et al. Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis. Lancet. 2019;394(10202):939–951. doi:10.1016/S0140-6736(19)31135-331303314
   PubMed Web of Science ®Google Scholar